dysfunction.
23
Methods The nonlinear mixed effects modeling tool NONMEM (version7.3, ICON 24 Development Solutions) was used to develop the PPK model of morinidazole.
25
Results One-compartment model was conducted to establish the morinidazole PPK 26 model. Disease condition was the significant covariate for CL and weight was the 27 significant covariate for V. The AUC 0-∞ was 120. 44±37.05 (79.25-207.20 ) μg×h/mL 28 in hepatic impairment group and was 79. 46±23.71 (42.94-116.75 ) μg×h/mL in control 
Post-hoc analysis and Simulations

163
The AUC 0-24 of individuals and the change of AUC 0-24 based on Child-Pugh 
PPK Modeling Analysis
178
Basic Model
179
The plasma concentration of 24 subjects was used to build the model (Figure 1 ).
180
The Child-Pugh score of 12 moderate hepatic impaired subjects caused by chronic 181 virus hepatitis induced cirrhosis was from 7 to 9 (average was 8 
209
The GOF figure of model evaluation showed that both population and individual Figure 3 showed the results of VPC using 1000 monte carlo simulations. The 
234
PK Parameters of Individuals
235
The AUC 0-∞ was 120. 44±37.05 (79.25-207.20) 
248
The correlation between AUC 0-24 and Child-Pugh score was showed in Figure 4 . showed that the correlation coefficient of AST, ALT and PT was less than 0.05.
255
Discussion
256
To our knowledge, this study was the first study to explore the 257 population-pharmacokinetics of morinidazole injection. Both one-compartment and 258 two-compartment model were performed in the study. The result showed that 259 one-compartment model with first-order elimination was optimal for pharmacokinetic 260 data modeling.
261
Moderate haptic impairment was the significant covariate for CL and the weight 262 was the significant covariate for V based on the result of this PPK study.
China(8). Hepatitis B was the cause of hepatic impairment of all the 12 subjects.
265
Child-Pugh score is recommended by FDA to assess the liver function in the PK study 266 of hepatic impaired population(9). Besides Child-Pugh score, MELD score and ALBI
267
Grade are conducted to assess the liver function in clinical practice as well.
268
Child-Pugh is widely used with the index of the synthetic function (ALB and PT) and were used to reassess the liver function of the subjects in this study.
273
MELD score uses serum creatinine, international normalized ratio (INR) and TB
274
as indexes, which reflect the renal function, synthetic and elimination function of liver. of severe renal impaired subjects was 1.4 time higher than that of the controlled 306 healthy subjects. Although the major metabolite (M4-1) of morinidazole was 7 times 307 higher in severe renal impaired subjects, the concentration was low(4). So the dosage adjustment strategy was referred to PK parameters of unchanged morinidazole, not 309 the metabolite.
310
Our PPK study showed that the ratio of AUC 0-∞ of moderate hepatic impaired 311 subjects without impaired renal function to AUC 0-∞ of healthy matched subjects was 312 less than 2, meanwhile no SAE was reported from both groups in the PK study.
313
Therefore, there is no need to adjust the dosage of morindazole in patients with 314 moderate hepatic impairment and normal renal function. However, since the AEs 315 incidence had significant difference between the two group with a higher incidence in 316 liver function impaired group(2), safety monitoring during the administration of 317 morinidazole was considered for the hepatic impaired group. The ratio of AUC 0-∞ of 318 moderate hepatic impaired subjects combined with mild renal function impairment to
319
AUC 0-∞ of healthy matched subjects was more than 2. As a result, dosage adjustment 320 should be considered. The PK study of morinidazole in healthy subjects showed a 321 positively correlated relationship between dosage and AUC 0-t (r was 0.979) (3).
322
Morinidazole showed a linear relationship between dosage and AUC. BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate transaminase;
Cr: creatinine; eGFR: estimated glomerular filtration rate 
